What is the latest SHILPAMED stock price?
The latest stored price for SHILPAMED is Rs 625.45 as of 2026-07-20.
gimli
SHILPAMED stock AI analysis
SHILPAMED Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SHILPA MEDICARE LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available SHILPAMED price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹625.45
1W return
-0.75%
1M return
+13.44%
3M return
+52.09%
6M return
+124.02%
1Y return
+36.61%
Market cap
₹12,232.66 cr
PE
50.27
PB
4.72
ROE
+9.82%
ROCE
+11.97%
RSI
60.80
Turnover
₹25.89 cr
Why it can matter in screens
- Momentum: SHILPAMED is above 50DMA, above 200DMA; RSI is 60.80.
- Returns: 1D +0.84%, 1W -0.75%, 1M +13.44%, 3M +52.09%, 1Y +36.61%.
- Trend levels: 52W high ₹645.75, 52W low ₹267.00, off high -3.14%.
- Liquidity: latest turnover is ₹25.89 cr; volume vs 20D is +0.36%.
- Valuation/profitability: PE 50.27, PB 4.72, ROE +9.82%, ROCE +11.97%.
- Growth: 3Y sales CAGR +13.82%, 3Y profit CAGR n/a.
Quick Answers
Is SHILPAMED above its 50DMA and 200DMA?
SHILPAMED is above 50DMA, above 200DMA. The latest 50DMA is 545.23 and the latest 200DMA is 397.42.
What are SHILPAMED PE, ROE and ROCE?
SHILPAMED has PE 50.27, ROE +9.82%, and ROCE +11.97% in Gimli's latest available snapshot.
How has SHILPAMED performed recently?
SHILPAMED has returned +13.44% over 1 month, +52.09% over 3 months, and +36.61% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 436.99 cr | 164.73 cr | 107.79 cr | 5.51 |
| 2025-12-31 | 409.73 cr | 101.90 cr | 44.58 cr | 2.36 |
| 2025-09-30 | 369.97 cr | 109.92 cr | 44.07 cr | 1.12 |
| 2025-06-30 | 321.46 cr | 97.28 cr | 46.89 cr | 2.40 |
| 2025-03-31 | 330.82 cr | 58.55 cr | 14.51 cr | 0.74 |
| 2024-12-31 | 319.30 cr | 82.17 cr | 31.78 cr | 1.63 |
| 2024-09-30 | 343.80 cr | 90.61 cr | n/a | 0.46 |
| 2024-06-30 | 292.51 cr | 79.52 cr | 14.06 cr | 1.46 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,538.87 cr | 534.75 cr | 243.33 cr | 12.44 |
| 2025-03-31 | 1,286.43 cr | 348.31 cr | 78.30 cr | 4.02 |
| 2024-03-31 | 1,151.60 cr | 245.92 cr | 31.87 cr | 1.83 |
| 2023-03-31 | 1,043.45 cr | 113.47 cr | -32.53 cr | -1.88 |
| 2022-03-31 | 397.81 cr | 223.00 cr | 20.16 cr | 16.87 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,705.61 cr | 41.26 cr | 659.86 cr | 2,591.20 cr |
| 2025-03-31 | 3,310.71 cr | 25.97 cr | 587.75 cr | 2,363.70 cr |
| 2024-03-31 | 3,093.24 cr | 30.23 cr | 937.39 cr | 1,792.34 cr |
| 2023-03-31 | 2,903.93 cr | 21.32 cr | 797.89 cr | 1,774.36 cr |
| 2022-03-31 | 2,875.50 cr | 33.83 cr | 683.29 cr | 1,811.15 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 342.18 cr | -28.45 cr | n/a |
| 2025-03-31 | 132.27 cr | -111.41 cr | n/a |
| 2024-03-31 | 136.67 cr | -47.89 cr | n/a |
| 2023-03-31 | 179.92 cr | -46.74 cr | n/a |
| 2022-03-31 | 105.13 cr | -226.69 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +40.13% | +11.38% | +8.05% | +4.21% | +40.43% | +8.73% |
| 2026-03-31 | +40.13% | +11.08% | +8.58% | +5.15% | +40.21% | +8.73% |
| 2025-12-31 | +40.13% | +10.97% | +8.33% | +5.20% | +40.56% | +8.73% |
| 2025-09-30 | +44.23% | +10.92% | +7.67% | +4.26% | +37.18% | +7.92% |
| 2025-06-30 | +44.23% | +11.20% | +7.46% | +4.05% | +37.11% | +7.92% |
| 2025-03-31 | +44.23% | +10.97% | +7.55% | +4.05% | +37.25% | +7.92% |
| 2024-12-31 | +44.23% | +9.90% | +8.27% | +4.89% | +37.60% | +7.92% |
| 2024-09-30 | +44.33% | +9.58% | +8.18% | +5.09% | +37.90% | +7.90% |
| 2024-06-30 | +44.39% | +9.08% | +7.61% | +5.03% | +38.92% | +90.41% |
| 2024-04-13 | +44.39% | +9.68% | +7.54% | +5.01% | +38.39% | +90.41% |
| 2024-03-31 | +50.01% | +5.63% | +1.65% | +1.55% | +42.71% | +90.41% |
| 2023-12-31 | +50.01% | +8.52% | +0.06% | +0.06% | +41.41% | +90.41% |
| 2023-09-30 | +50.01% | +8.60% | +0.41% | +0.04% | +40.99% | +90.41% |
| 2023-06-30 | +50.01% | +10.26% | +0.37% | +0.00% | +39.37% | +12.90% |
| 2023-03-31 | +50.01% | +13.74% | +0.54% | +0.00% | +35.71% | +12.90% |
| 2022-12-31 | +50.01% | +15.33% | +0.61% | +0.05% | +34.04% | +1.38% |
| 2022-09-30 | +50.01% | +14.46% | +1.76% | +1.01% | +33.77% | +0.81% |
| 2022-06-30 | +50.01% | +0.00% | +16.40% | n/a | n/a | +0.81% |
| 2022-03-31 | +50.01% | +0.00% | +16.34% | n/a | n/a | +0.81% |
| 2021-12-31 | +50.01% | +0.00% | +17.45% | n/a | n/a | +0.81% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze SHILPA MEDICARE with valuation, momentum and industry peers
- Compare SHILPAMED with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SHILPAMED with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.